Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CQDM is very pleased to announce that Janssen is joining its public-private consortium to support highly innovative, collaborative research in Canada to accelerate drug discovery and development, in order to bring better treatments to patients.
Subscribe to our email newsletter
The new partnership with Janssen brings to nine the number of pharmaceutical companies around CQDM’s table, increasing the financial leverage that partners generate together.
Thanks to CQDM’s unique business model, this leverage can go up to 25 times, depending on the funding program and co-funding partners, allowing the development of breakthrough tools, technologies and platforms which can help to bring faster health solutions from bench to bedside, at a much lower cost.
Janssen is joining CQDM’s precompetitive research consortium as a program specific member and will be associated with the Explore Program.
This program funds highly innovative, unconventional, high-risk and high-reward research from Quebec and Ontario that may significantly accelerate drug discovery across the industry by increasing R&D productivity and developing new research avenues. It also supports early concept validation of disruptive technologies to enhance drug discovery.
"We are very happy to welcome to CQDM such an innovative partner as Janssen. Janssen has been very creative in establishing strategic collaborations with academia, biotech and other pharmaceutical companies to tap into the best science to leverage expertise. We will certainly benefit from their experience," said Diane Gosselin, President and CEO of CQDM.
"The addition of Janssen to the consortium also demonstrates the quality and uniqueness of the collaborative environment we offer to our stakeholders to address the most important unmet medical needs."
In addition to its financial contribution, Janssen will also contribute in-kind to the consortium, namely by having a representative on CQDM’s Explore Advisory Committee, as well as key scientists involved in CQDM’s unique mentorship program.
Mentors are the ultimate users of the technologies that are being developed under CQDM’s funding and are well positioned to help the funded researchers better align the technologies with industry needs. As of today, about 100 mentors from CQDM’s pharmaceutical company members have been involved in 35 projects conducted by a network of 460 researchers throughout Canada.